DK2493870T3 - CHROMENONDERIVATER WITH antitumor activity - Google Patents
CHROMENONDERIVATER WITH antitumor activity Download PDFInfo
- Publication number
- DK2493870T3 DK2493870T3 DK10769052.1T DK10769052T DK2493870T3 DK 2493870 T3 DK2493870 T3 DK 2493870T3 DK 10769052 T DK10769052 T DK 10769052T DK 2493870 T3 DK2493870 T3 DK 2493870T3
- Authority
- DK
- Denmark
- Prior art keywords
- ethyl
- oxo
- chromene
- morpholino
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09306017 | 2009-10-27 | ||
| PCT/GB2010/051788 WO2011051704A1 (en) | 2009-10-27 | 2010-10-25 | Chromenone derivatives with anti-tumour activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2493870T3 true DK2493870T3 (en) | 2015-02-23 |
Family
ID=43085922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10769052.1T DK2493870T3 (en) | 2009-10-27 | 2010-10-25 | CHROMENONDERIVATER WITH antitumor activity |
Country Status (41)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2307400B1 (en) | 2008-05-30 | 2014-04-23 | Amgen, Inc | Inhibitors of pi3 kinase |
| US8399460B2 (en) * | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
| US8530470B2 (en) * | 2011-04-13 | 2013-09-10 | Astrazeneca Ab | Chromenone derivatives |
| RU2644769C2 (ru) | 2013-01-23 | 2018-02-14 | Астразенека Аб | Химические соединения |
| US9763950B2 (en) * | 2013-03-04 | 2017-09-19 | Astrazeneca Ab | Combination treatment |
| JP6455995B2 (ja) | 2014-06-13 | 2019-01-23 | ギリアード サイエンシーズ， インコーポレイテッド | ホスファチジルイノシトール３−キナーゼ阻害剤 |
| ES2833025T3 (es) | 2014-06-13 | 2021-06-14 | Gilead Sciences Inc | Inhibidores de fosfatidilinositol 3-quinasa |
| KR20170015508A (ko) | 2014-06-13 | 2017-02-08 | 길리애드 사이언시즈, 인코포레이티드 | 포스파티딜이노시톨 3-키나제 억제제로서의 퀴나졸리논 유도체 |
| EP3154969B1 (en) | 2014-06-13 | 2019-10-09 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| US9499523B2 (en) | 2014-06-13 | 2016-11-22 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
| CN104744376A (zh) * | 2015-03-14 | 2015-07-01 | 长沙深橙生物科技有限公司 | 一种2-异丙基嘧啶衍生物的制备方法 |
| CN104803921A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种苯取代嘧啶衍生物的制备方法 |
| KR101766731B1 (ko) | 2015-06-23 | 2017-08-10 | 충남대학교산학협력단 | 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물 |
| KR102630111B1 (ko) * | 2015-10-09 | 2024-01-25 | 얀센 파마슈티카 엔브이 | PI3Kβ 저해제로서의 퀴녹살린 및 피리도피라진 유도체 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| WO2018057808A1 (en) | 2016-09-23 | 2018-03-29 | Gilead Sciences, Inc. | Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| AR121719A1 (es) * | 2020-04-03 | 2022-06-29 | Petra Pharma Corp | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades |
| KR20210141214A (ko) * | 2020-05-15 | 2021-11-23 | 제이투에이치바이오텍 (주) | 3원환 화합물 및 이의 의약 용도 |
| CN117615763A (zh) * | 2021-02-01 | 2024-02-27 | 健道生物医药有限公司 | 磷酸肌醇3激酶β抑制剂及其组合物和制备方法 |
| AU2022268900B2 (en) | 2021-05-03 | 2024-12-19 | Petra Pharma Corporation | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
| BR112023022580A2 (pt) * | 2021-05-03 | 2024-01-09 | Petra Pharma Corp | Inibidores alostéricos de cromenona de fosfoinositídeo 3-quinase (pi3k) para o tratamento de doenças |
| IL308776A (en) | 2021-05-27 | 2024-01-01 | Petra Pharma Corp | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer |
| TW202329930A (zh) | 2021-09-30 | 2023-08-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑 |
| EP4412606A4 (en) * | 2021-10-07 | 2025-09-24 | Relay Therapeutics Inc | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF |
| WO2023104111A1 (en) * | 2021-12-08 | 2023-06-15 | Nanjing Zenshine Pharmaceuticals Co., Ltd. | Fused heterocyclic compounds as pi3kalpha inhibitors |
| WO2024003241A1 (en) | 2022-06-30 | 2024-01-04 | Astrazeneca Ab | Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4 |
| WO2024081904A1 (en) * | 2022-10-14 | 2024-04-18 | Genesis Therapeutics, Inc. | Methods for treating cancer |
| WO2025026442A1 (zh) * | 2023-08-02 | 2025-02-06 | 郑州同源康医药有限公司 | 稠环类化合物及其用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6027A (en) * | 1849-01-09 | Rotary blacksmith s twyer | ||
| FI912995A7 (fi) | 1988-12-21 | 1991-06-19 | Upjohn Co | Antiateroskleroottisia ja antitromboottisia 1-bentsopyran-4-oneja ja 2 -amino-1,3-bentsoksatsin-4-oneja |
| WO1991019707A2 (en) | 1990-06-20 | 1991-12-26 | The Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| DE4318756A1 (de) | 1993-06-05 | 1994-12-08 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| PT885198E (pt) | 1996-03-05 | 2002-06-28 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| KR100838617B1 (ko) | 1999-02-10 | 2008-06-16 | 아스트라제네카 아베 | 혈관형성 억제제로서의 퀴나졸린 유도체 |
| ATE551325T1 (de) | 2000-01-24 | 2012-04-15 | Astrazeneca Ab | Therapeutische morpholino-substituierte verbindungen |
| CA2406979A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
| CZ200331A3 (cs) | 2000-07-07 | 2003-04-16 | Angiogene Pharmaceuticals Limited | Deriváty kolchinolu jako inhibitory angiogeneze, způsob jejich přípravy a farmaceutická kompozice, která je obsahuje |
| US7598377B2 (en) * | 2002-08-16 | 2009-10-06 | Astrazeneca Ab | Inhibition of phosphoinositide 3-kinase β |
| AR053358A1 (es) * | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
| AU2006303037A1 (en) | 2005-10-21 | 2007-04-26 | Merz Pharma Gmbh & Co Kgaa | Chromenones and their use as modulators of metabotropic glutamate receptors |
| CN101506211B (zh) * | 2006-04-04 | 2013-05-22 | 加利福尼亚大学董事会 | 激酶拮抗剂 |
| WO2008064244A2 (en) | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
| EP2112145A1 (en) | 2008-04-24 | 2009-10-28 | AxoGlia Therapeutics S.A. | Chromenone derivatives useful for the treatment of neurodegenerative diseases |
| WO2010134082A1 (en) | 2009-05-21 | 2010-11-25 | Proteologics Ltd | Chromenone derivatives for treatment of cancer |
| US8399460B2 (en) * | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
-
2010
- 2010-10-22 US US12/909,968 patent/US8399460B2/en active Active
- 2010-10-25 AU AU2010311107A patent/AU2010311107B9/en not_active Ceased
- 2010-10-25 CN CN201410654983.0A patent/CN104447657B/zh not_active Expired - Fee Related
- 2010-10-25 CA CA2776994A patent/CA2776994C/en active Active
- 2010-10-25 HR HRP20150146TT patent/HRP20150146T1/hr unknown
- 2010-10-25 ES ES10769052T patent/ES2530943T3/es active Active
- 2010-10-25 PL PL10769052T patent/PL2493870T3/pl unknown
- 2010-10-25 DK DK10769052.1T patent/DK2493870T3/en active
- 2010-10-25 NZ NZ599457A patent/NZ599457A/en not_active IP Right Cessation
- 2010-10-25 JP JP2012535931A patent/JP5657010B2/ja not_active Expired - Fee Related
- 2010-10-25 RS RS20150090A patent/RS53813B1/sr unknown
- 2010-10-25 PH PH1/2012/500804A patent/PH12012500804A1/en unknown
- 2010-10-25 PT PT10769052T patent/PT2493870E/pt unknown
- 2010-10-25 IN IN3328DEN2012 patent/IN2012DN03328A/en unknown
- 2010-10-25 EP EP10769052.1A patent/EP2493870B1/en active Active
- 2010-10-25 MY MYPI2012001831A patent/MY179833A/en unknown
- 2010-10-25 ME MEP-2015-21A patent/ME02050B/me unknown
- 2010-10-25 PE PE2012000578A patent/PE20130149A1/es active IP Right Grant
- 2010-10-25 MX MX2012005027A patent/MX2012005027A/es active IP Right Grant
- 2010-10-25 BR BR112012010124A patent/BR112012010124B8/pt not_active IP Right Cessation
- 2010-10-25 WO PCT/GB2010/051788 patent/WO2011051704A1/en not_active Ceased
- 2010-10-25 KR KR1020127012933A patent/KR101738195B1/ko not_active Expired - Fee Related
- 2010-10-25 EA EA201200618A patent/EA020523B9/ru not_active IP Right Cessation
- 2010-10-25 CN CN201080060262.7A patent/CN102712615B/zh not_active Expired - Fee Related
- 2010-10-25 SI SI201030875T patent/SI2493870T1/sl unknown
- 2010-10-25 UA UAA201206000A patent/UA107474C2/uk unknown
- 2010-10-26 AR ARP100103937 patent/AR078786A1/es active IP Right Grant
- 2010-10-27 TW TW099136762A patent/TWI483939B/zh not_active IP Right Cessation
- 2010-10-27 UY UY32978A patent/UY32978A/es not_active Application Discontinuation
- 2010-10-27 SA SA110310808A patent/SA110310808B1/ar unknown
-
2012
- 2012-04-15 IL IL219191A patent/IL219191A0/en not_active IP Right Cessation
- 2012-04-25 CL CL2012001056A patent/CL2012001056A1/es unknown
- 2012-04-26 CO CO12068977A patent/CO6541528A2/es active IP Right Grant
- 2012-04-27 EC ECSP12011838 patent/ECSP12011838A/es unknown
- 2012-04-27 DO DO2012000124A patent/DOP2012000124A/es unknown
- 2012-04-27 GT GT201200126A patent/GT201200126A/es unknown
- 2012-04-27 CU CU2012000069A patent/CU20120069A7/es unknown
- 2012-04-27 CR CR20120217A patent/CR20120217A/es unknown
- 2012-04-27 NI NI201200081A patent/NI201200081A/es unknown
- 2012-04-27 HN HN2012000889A patent/HN2012000889A/es unknown
-
2013
- 2013-02-13 US US13/765,850 patent/US8673906B2/en active Active
-
2014
- 2014-01-24 US US14/163,105 patent/US9029374B2/en active Active
- 2014-11-20 JP JP2014235289A patent/JP5872016B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-12 SM SM201500036T patent/SMT201500036B/xx unknown
- 2015-02-13 CY CY20151100157T patent/CY1116143T1/el unknown
- 2015-04-08 US US14/681,244 patent/US20160060240A1/en not_active Abandoned
-
2016
- 2016-03-24 US US15/079,633 patent/US9718800B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2493870T3 (en) | CHROMENONDERIVATER WITH antitumor activity | |
| AU2012241594B2 (en) | Chromenone compounds as PI 3 -kinase inhibitors for the treatment of cancer | |
| HK1174027B (en) | Chromenone derivatives with anti-tumour activity | |
| HK1206335B (en) | Chromenone derivatives with anti-tumour activity | |
| HK1193823B (en) | Chromenone compounds as pi 3 -kinase inhibitors for the treatment of cancer |